Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ML-04
- Development stage
- Unknown
- Lead developer
- MapLight Therapeutics
- Modality
- Peptides
- Administration
- Oral
01
Overview
ML-04 is a patented oral form of human chorionic gonadotropin (hCG) that was under development by Milkhaus Laboratory. Its mechanism of action involves inhibition of interleukin 6 and interleukin 8. The drug was being investigated primarily for benign prostatic hyperplasia, myelodysplastic syndromes, and prostatitis. More recently, a formulation called ML-004 has been investigated for autism spectrum disorder (ASD) by MapLight Therapeutics, focusing on social deficit and irritability symptoms in ASD patients.
- Other names
- Urological therapeutics, MilkhausHuman chorionic gonadotropin (benign prostate hyperplasia/prostatitis/cancer)
02
Targets
IL-6 (Interleukin 6)IL8 (C-X-C Motif Chemokine Ligand 8)
Beyond the preview
Go deeper on ML-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ML-04.